Centre National De La Recherche Scientifique

M Et P Pharma Ag

UniversitÉde Strasbourg

Elisabeth Traiffort

Martial Ruat

Claudia Mattern

Hélène Faure

Michael Schumacher

André Mann

Maurizio Taddei

Fabrizio Manetti

Antonio Solinas

Angèle Schoenfelder

Hermine Roudaut

Seana O'Regan

François Meunier

Angele Schoenfelder

Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.

Treatment of demyelinating diseases

The present invention relates to the use of acylthiourea or acylurea derivatives for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, and also to novel acylthiourea or acylurea derivatives as such, to their use as a medicinal product, and to pharmaceutical compositions containing them.

N-acylthiourea and N-acylurea inhibitors of the Hedgehog protein signalling pathway

The present invention relates to acyl guanidine derivatives modulating the hedgehog protein signaling pathway to be used as drugs, in particular for treating diseases involving a tissue dysfunction associated with a deregulation of the hedgehog protein signaling pathway, as well as to pharmaceutical compositions containing same. The present invention also relates to novel acyl guanidine derivatives as such.

Acyl guanidine derivatives modulating the hedgehog protein signaling pathway

The invention relates to a novel use of compounds having formula (I), including mifepristone (RU 486 or RU 38 486) and the derivative salts thereof, for the preparation of a medicament that can modulate (activate or inhibit) the Hedgehog protein signalling pathway, which is intended for the treatment of pathologies involving a tissue dysfunction linked to deregulation of said pathway.

Use of mifepristone and derivatives therefor as Hedgehog protein signaling pathway modulators and applications of same

The invention concerns the identification of a novel family of CTL (Choline Transporter Like) genes, in particular hCTL1 and hCTL2, involved in the metabolism and/or transport of choline in cells such as the intestinal tract cells, nervous cells, in particular motoneurons, sensitive neurons, neurons of the nucleus dorsalis of the spinal cord and oligodendrocytes. The invention opens up new prospects in particular for the treatment of familial dysautonomia, and Tangier disease. More generally, the identification of CTL genes enables to develop new strategies for treating diseases of the nervous system, in particular neurodegenerative demyelenating diseases, particularly Alzheimer disease, Parkinson disease and Huntington disease.

Choline transport like (CTL) membrane proteins involved in choline transport

Growing community of inventors

Paris, France

Elisabeth Traiffort